202 related articles for article (PubMed ID: 38216572)
1. Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.
Vasudevan HN; Payne E; Delley CL; John Liu S; Mirchia K; Sale MJ; Lastella S; Nunez MS; Lucas CG; Eaton CD; Casey-Clyde T; Magill ST; Chen WC; Braunstein SE; Perry A; Jacques L; Reddy AT; Pekmezci M; Abate AR; McCormick F; Raleigh DR
Nat Commun; 2024 Jan; 15(1):477. PubMed ID: 38216572
[TBL] [Abstract][Full Text] [Related]
2. Neurofibromatosis.
McClatchey AI
Annu Rev Pathol; 2007; 2():191-216. PubMed ID: 18039098
[TBL] [Abstract][Full Text] [Related]
3. Mouse models of neurofibromatosis 1 and 2.
Gutmann DH; Giovannini M
Neoplasia; 2002; 4(4):279-90. PubMed ID: 12082543
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.
Carroll SL
Acta Neuropathol; 2012 Mar; 123(3):321-48. PubMed ID: 22160322
[TBL] [Abstract][Full Text] [Related]
5. Advances in the treatment of neurofibromatosis-associated tumours.
Lin AL; Gutmann DH
Nat Rev Clin Oncol; 2013 Nov; 10(11):616-24. PubMed ID: 23939548
[TBL] [Abstract][Full Text] [Related]
6. Molecular Analysis of Hybrid Neurofibroma/Schwannoma Identifies Common Monosomy 22 and α-T-Catenin/CTNNA3 as a Novel Candidate Tumor Suppressor.
Stahn V; Nagel I; Fischer-Huchzermeyer S; Oyen F; Schneppenheim R; Gesk S; Bohring A; Chikobava L; Young P; Gess B; Werner M; Senner V; Harder A
Am J Pathol; 2016 Dec; 186(12):3285-3296. PubMed ID: 27765635
[TBL] [Abstract][Full Text] [Related]
7. New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.
Williams KB; Largaespada DA
Genes (Basel); 2020 Apr; 11(5):. PubMed ID: 32353955
[TBL] [Abstract][Full Text] [Related]
8. The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics.
Carroll SL
Am J Pathol; 2016 Mar; 186(3):464-77. PubMed ID: 26740486
[TBL] [Abstract][Full Text] [Related]
9. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
Widemann BC; Acosta MT; Ammoun S; Belzberg AJ; Bernards A; Blakeley J; Bretscher A; Cichowski K; Clapp DW; Dombi E; Evans GD; Ferner R; Fernandez-Valle C; Fisher MJ; Giovannini M; Gutmann DH; Hanemann CO; Hennigan R; Huson S; Ingram D; Kissil J; Korf BR; Legius E; Packer RJ; McClatchey AI; McCormick F; North K; Pehrsson M; Plotkin SR; Ramesh V; Ratner N; Schirmer S; Sherman L; Schorry E; Stevenson D; Stewart DR; Ullrich N; Bakker AC; Morrison H
Am J Med Genet A; 2014 Mar; 164A(3):563-78. PubMed ID: 24443315
[TBL] [Abstract][Full Text] [Related]
10. CD44 expression is aberrant in benign Schwann cell tumors possessing mutations in the neurofibromatosis type 2, but not type 1, gene.
Sherman L; Jacoby LB; Lampe J; Pelton P; Aguzzi A; Herrlich P; Ponta H
Cancer Res; 1997 Nov; 57(21):4889-97. PubMed ID: 9354454
[TBL] [Abstract][Full Text] [Related]
11. A mouse embryonic stem cell model of Schwann cell differentiation for studies of the role of neurofibromatosis type 1 in Schwann cell development and tumor formation.
Roth TM; Ramamurthy P; Ebisu F; Lisak RP; Bealmear BM; Barald KF
Glia; 2007 Aug; 55(11):1123-33. PubMed ID: 17597122
[TBL] [Abstract][Full Text] [Related]
12. Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients.
Rosenbaum C; Kluwe L; Mautner VF; Friedrich RE; Müller HW; Hanemann CO
Neurobiol Dis; 1998 Jul; 5(1):55-64. PubMed ID: 9702788
[TBL] [Abstract][Full Text] [Related]
13. [Neurofibromatosis].
Matthies C; Rampeltshammer E; Breun M
Fortschr Neurol Psychiatr; 2023 May; 91(5):213-232. PubMed ID: 37192611
[TBL] [Abstract][Full Text] [Related]
14. Neurofibromatoses: part 1 - diagnosis and differential diagnosis.
Rodrigues LO; Batista PB; Goloni-Bertollo EM; de Souza-Costa D; Eliam L; Eliam M; Cunha KS; Darrigo-Junior LG; Ferraz-Filho JR; Geller M; Gianordoli-Nascimento IF; Madeira LG; Malloy-Diniz LF; Mendes HM; de Miranda DM; Pavarino EC; Baptista-Pereira L; Rezende NA; Rodrigues Lde O; da Silva CM; de Souza JF; de Souza ML; Stangherlin A; Valadares ER; Vidigal PV
Arq Neuropsiquiatr; 2014 Mar; 72(3):241-50. PubMed ID: 24676443
[TBL] [Abstract][Full Text] [Related]
15. Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type I-related neoplasms of the peripheral nervous system.
Brossier NM; Carroll SL
Brain Res Bull; 2012 May; 88(1):58-71. PubMed ID: 21855613
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis.
Nagel A; Huegel J; Petrilli A; Rosario R; Victoria B; Hardin HM; Fernandez-Valle C
Oncogene; 2024 Mar; 43(13):921-930. PubMed ID: 38336988
[TBL] [Abstract][Full Text] [Related]
17. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells.
Mashour GA; Ratner N; Khan GA; Wang HL; Martuza RL; Kurtz A
Oncogene; 2001 Jan; 20(1):97-105. PubMed ID: 11244508
[TBL] [Abstract][Full Text] [Related]
18. Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use.
Bettegowda C; Upadhayaya M; Evans DG; Kim A; Mathios D; Hanemann CO;
Neurology; 2021 Aug; 97(7 Suppl 1):S91-S98. PubMed ID: 34230207
[TBL] [Abstract][Full Text] [Related]
19. How does the Schwann cell lineage form tumors in NF1?
Carroll SL; Ratner N
Glia; 2008 Nov; 56(14):1590-1605. PubMed ID: 18803326
[TBL] [Abstract][Full Text] [Related]
20. Rac1 is required for Prkar1a-mediated Nf2 suppression in Schwann cell tumors.
Manchanda PK; Jones GN; Lee AA; Pringle DR; Zhang M; Yu L; La Perle KM; Kirschner LS
Oncogene; 2013 Jul; 32(30):3491-9. PubMed ID: 23045281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
